Related Experiment Video
Updated: Jan 20, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
Published on: March 17, 2020
Somatostatin receptor 2 targeting in small cell lung carcinoma: perspectives
Jonathan M Lehman1,2,3, Pierre P aMassion1,2,3
1Division of Medical Oncology, Thoracic Program, Vanderbilt Ingram Cancer Center, Nashville, TN, USA.
Abstract:
Small Cell lung carcinoma (SCLC) is the most lethal and aggressive subtype of lung cancer. Novel targeting approaches and agents are desperately needed. In this perspectives, we briefly explore recent data published in the International Journal of Cancer suggesting Somatostatin Receptor 2 (SSTR2) as a viable target for SCLC, summarize the current clinical trial space, and describe promising new research and clinical directions for Somatostatin Receptor 2 targeting in SCLC.
Insights
Small Cell Lung Carcinoma (SCLC) is aggressive. Somatostatin Receptor 2 (SSTR2) shows promise as a new therapeutic target for SCLC, with ongoing research exploring its clinical potential.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Small Cell Lung Carcinoma (SCLC) is a highly aggressive cancer with limited treatment options.
- There is a critical need for novel therapeutic strategies to improve outcomes for SCLC patients.
Purpose of the Study:
- To explore Somatostatin Receptor 2 (SSTR2) as a potential therapeutic target for SCLC.
- To summarize the current clinical landscape of SSTR2 targeting in SCLC.
- To outline future research and clinical directions for SCLC treatment.
Main Methods:
- Review of recent data from the International Journal of Cancer regarding SSTR2 in SCLC.
- Analysis of the current clinical trial landscape for SCLC therapies.
- Exploration of emerging research and clinical strategies for SSTR2-targeted SCLC treatment.
Main Results:
- Recent findings suggest SSTR2 is a viable target for SCLC.
- The clinical trial space for SCLC is evolving, with potential for SSTR2-based interventions.
- Promising new research avenues are emerging for SSTR2 targeting in SCLC.
Conclusions:
- Somatostatin Receptor 2 (SSTR2) represents a promising novel target for Small Cell Lung Carcinoma (SCLC).
- Further research and clinical trials are warranted to develop SSTR2-targeted therapies for SCLC.
- Targeting SSTR2 could offer a new therapeutic avenue for this aggressive cancer.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
Related Concept Videos
Internal Receptors
Psychodynamic Perspectives on Personality
Psychodynamic theorists argue that unconscious...
Types of Receptors: Cell Surface Receptors
The Behavioral Perspective on Personality
Criticisms of the Evolutionary Perspective
Evolutionary psychology provides one explanation for these findings, suggesting...
Social Cognitive Perspective on Personality